IMNN vs PMA Comparison

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Ming Shing Group Holdings Ltd is a holding company engaged through its subsidiaries in wet trades works, including plastering, tile laying, brick laying, floor screeding and marble works. To a much lesser extent, it provides small-scale fitting out services, such as renovation works, and engages in trading of wines and spirits. Through its subsidiaries, it is mainly engaged in private sector projects in Hong Kong, involving private residential and commercial developments, while public sector projects mainly involve public residential developments, infrastructure and public facilities developments. The Company operates through two segments: Provision of Wet Trades Works and Trading of Wines and Spirits, with Trading of Wines and Spirits generating the maximum revenue.